Masoabi Sefojane: In Africa 88% of Hemophilia Remains Undiagnosed
Masoabi Sefojane, Geographic Expansion Lead, Africa and Asia Pacific at MicroHealth , shared a post on LinkedIn:
”The World Federation of Haemophilia identifies 37% of people with haemophilia globally.
In low-income countries? 11%.
In Africa? An estimated 88% remain undiagnosed.
Let me be direct: these numbers represent invisibility by design.
Not because diagnosis is impossible.
But because the systems to find people were built for certain geographies and certain people.
When my brother was 6 years old in Phuthaditjhaba, South Africa, He didn’t exist in any global haemophilia dataset.
He was bleeding, my family was desperate, but he was invisible. No screening protocol would find him.
No registry would record him. No system knew he existed. This could have been my story if it wasn’t for my brothers.
Ask any bleeding disorder patient in the global south and you will hear similar stories and a pattern will also emerge.
Meanwhile, a child born with the same severe haemophilia A in Amsterdam? Known by age 1. Registered. Part of the data that shapes global priorities.
Same disease. Different visibility.
Here’s what the data shows: Africa, with 18% of the world’s population, represents less than 3% of identified haemophilia patients globally.
That’s not because haemophilia is rare in Africa. It’s because the systems designed to find haemophilia were never designed to reach Africa.
The invisibility isn’t accidental. It’s structural.
When a patient is invisible, they don’t exist in clinical trials. They’re not counted in epidemiology.
They don’t influence treatment guidelines. Their outcomes don’t matter because nobody’s measuring them.
The question we need to ask: Are we actually looking for these patients?
Or have we built systems that only find the ones in certain places?
Because that’s the real diagnosis gap.”
Stay updated with Hemostasis Today.
-
Jun 6, 2026, 13:01Kathleen Freson: αIIbβ3’s Hidden Role in Platelet Production
-
Jun 6, 2026, 12:22Jonas Kingo: Factor XI at the Crossroads of Hormonal Regulation and Thrombosis at ISTH 2026
-
Jun 6, 2026, 12:06Reza Shojaei: Why Dried Plasma May Be the Most Important Plasma Innovation in Decades
-
Jun 6, 2026, 08:25Marina Tarunina: Engineered Platelets From Human iPSCs Support Haemostasis Without Thromboembolism
-
Jun 6, 2026, 08:21Razieh Parizad: Systematic Review Evaluates the Future Role of Factor XI Inhibitors in Stroke Prevention
-
Jun 6, 2026, 08:10Vrinda Trivedi: Hematologic Emergencies and Anticoagulation Strategies Spotlighted at CCCES 2026
-
Jun 6, 2026, 08:02Krisstina Gowin: Could the Gut Microbiome Be the Missing Link in Hematology Outcomes?
-
Jun 6, 2026, 07:59Razan Awan: Large Cohort Study Questions Routine Use of Dual Antiplatelet Therapy After TAVI
-
Jun 6, 2026, 07:28Ahmed Dheyaa Al-Obaidi: Retrospective Study Highlights the Role of Transient Elastography in Pediatric Hepatic Fibrosis